These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Tyler K; Hillard CJ; Greenwood-Van Meerveld B Eur J Pharmacol; 2000 Dec; 409(2):207-11. PubMed ID: 11104836 [TBL] [Abstract][Full Text] [Related]
10. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study. Petitet F; Jeantaud B; Capet M; Doble A Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978 [TBL] [Abstract][Full Text] [Related]
11. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686 [TBL] [Abstract][Full Text] [Related]
12. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. Smith SR; Terminelli C; Denhardt G J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163 [TBL] [Abstract][Full Text] [Related]
13. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794 [TBL] [Abstract][Full Text] [Related]
14. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Darmani NA Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Ihenetu K; Molleman A; Parsons ME; Whelan CJ Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928 [TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Mato S; Pazos A; Valdizán EM Eur J Pharmacol; 2002 May; 443(1-3):43-6. PubMed ID: 12044790 [TBL] [Abstract][Full Text] [Related]
17. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. MacLennan SJ; Reynen PH; Kwan J; Bonhaus DW Br J Pharmacol; 1998 Jun; 124(4):619-22. PubMed ID: 9690851 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Pertwee RG; Griffin G; Lainton JA; Huffman JW Eur J Pharmacol; 1995 Sep; 284(3):241-7. PubMed ID: 8666005 [TBL] [Abstract][Full Text] [Related]
19. AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Landsman RS; Makriyannis A; Deng H; Consroe P; Roeske WR; Yamamura HI Life Sci; 1998; 62(9):PL109-13. PubMed ID: 9496703 [TBL] [Abstract][Full Text] [Related]
20. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Hosohata Y; Quock RM; Hosohata K; Makriyannis A; Consroe P; Roeske WR; Yamamura HI Eur J Pharmacol; 1997 Feb; 321(1):R1-3. PubMed ID: 9083796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]